Assembly Biosciences Inc. (ASMB)
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes
📈 **POSITIVE** • Low confidence analysis (51%) • Moderate positive clinical data • Good growth prospects **Sentiment:** Positive (55%) **Content type:** Clinical